Alpelisib Discontinuation in Patients With H R +, Human Epidermal Growth Factor Receptor2 Neg Breast Cancer

Alpelisib Discontinuation in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Alpelisib is a phosphoinositide-3-kinase inhibitor approved for hormone-receptor-positive, PIK3CA-mutated metastatic breast cancer. However, length of drug exposure, maximum-tolerated dose, and therefore clinical response can vary significantly outside of the trial setting. This study evaluates our center's "real world" experience with alpelisib and focuses on duration of therapy and factors associated with cancer progression.

https://www.practiceupdate.com/c/130810/67/13/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849617

Piqray (alpelisib) - Novartis.
FDA approved - May 2019 for breast cancer

The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier.

Source :19-Jan-2022Kazia Corporate Presentation.

IMO, one door closes for alpelisib, with another door opening the possibility for paxalisib.

Regards.